Special Issue

Antibiotic Treatment in Dermatology

Message from the Guest Editors

Both topical and systemic antibiotics have been used in dermatology ranging from cutaneous infections, to acne and rosacea, to inflammatory dermatoses, and neutrophilic dermatoses, and also surgical prophylaxis and wound healing.

Dermatologists prescribe more oral antibiotic courses per clinician than any other specialty, and many of these courses of antibiotics are prescribed for several months in duration. The prolonged and intermittent use of broad-spectrum antibiotics has been associated with the development of antimicrobial resistance and permanent perturbation of the human microbiome. Clinical consequences of antibiotic resistance include reduced treatment effectiveness and transmission of resistance to other bacteria.

This Special Issue titled "Antibiotic Treatment in Dermatology" will focus on the utility of antibiotics to treat skin disease, current trends, the impact of broadspectrum antibiotics on the microbiome and resistance, unmet needs for narrow-spectrum antibiotics, antibiotic stewardship, and future directions. We kindly invite original research articles as well as commentaries and review papers. All articles will be peer reviewed.

Guest Editors

Dr. Ayman Grada

Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

Dr. Christopher Bunick

Department of Dermatology, Yale School of Medicine, New Haven, CT, USA

Deadline for manuscript submissions

closed (31 December 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/104097

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

